Fate Therapeutics (FATE) Return on Capital Employed (2013 - 2026)
Fate Therapeutics (FATE) posted Return on Capital Employed of 51.4% for Q1 2026, down 2.74% on a QoQ basis from 50.03% in Q4 2025, and down 20.0% year-over-year from 64.25% in Q1 2025.
Fate Therapeutics (FATE) Return on Capital Employed (2013 - 2026) Analysis & Trends
Fate Therapeutics' Return on Capital Employed history runs 14 years deep, the most recent figure standing at 51.4% for Q1 2026.
- Quarterly Return on Capital Employed fell 20.0% year-over-year to 51.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 51.4% (down 20.0% YoY) and the FY2025 annual result came in at 42.97%, up 538.0% from the prior year.
- Return on Capital Employed was 51.4% for Q1 2026 at Fate Therapeutics, down from 50.03% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 30.2% in Q1 2022 and bottomed at 53.96% in Q2 2025.
- A 5-year average of 44.73% and a median of 43.23% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 2654 bps — and 2023, when it soared 1107 bps.
- Fate Therapeutics' Return on Capital Employed stood at 50.27% in 2022, then grew by 22 bps to 39.21% in 2023, then fell by 25 bps to 48.98% in 2024, then declined by 2 bps to 50.03% in 2025, then fell by 3 bps to 51.4% in 2026.
- Business Quant data shows FATE's Return on Capital Employed at 51.4% in Q1 2026, 50.03% in Q4 2025, and 53.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - | -51.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.40% |
| Dec 31, 2025 | -50.03% |
| Sep 30, 2025 | -53.02% |
| Jun 30, 2025 | -53.96% |
| Mar 31, 2025 | -51.21% |
| Dec 31, 2024 | -48.98% |
| Sep 30, 2024 | -41.44% |
| Jun 30, 2024 | -37.99% |
| Mar 31, 2024 | -43.23% |
| Dec 31, 2023 | -39.21% |
| Sep 30, 2023 | -39.56% |
| Jun 30, 2023 | -42.99% |
| Mar 31, 2023 | -42.39% |
| Dec 31, 2022 | -50.27% |
| Sep 30, 2022 | -46.47% |
| Jun 30, 2022 | -37.99% |
| Mar 31, 2022 | -30.20% |
| Dec 31, 2021 | -24.89% |
| Sep 30, 2021 | -19.93% |
| Jun 30, 2021 | -17.06% |